A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson's Disease (TEMPO-1 TRIAL)

Investigator: William Ondo, MD

Study Coordinator: Chelsea Kinney

Status: Enrolling

ClinicalTrials.gov Number: NCT04201093

Phone: 346.238.9068

Protocol Number: PRO00024995


The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
More to Explore